LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) Form 424B5 — Jun 4, 2026
Lixte Biotechnology Holdings (LIXT) is completing a private placement of 2,366,503 shares and 258,859 pre-funded warrants at $6.31 per unit, raising approximately $16.6 million in gross proceeds. The capital will be used for working capital and the clinical development of its lead cancer therapy candidate, LB-100. The filing highlights significant risks, including an auditor’s going concern qualification and a clinical trial hold at the Netherlands Cancer Institute due to two serious adverse events (SAEs) involving lung toxicity and fever/aphasia in patients treated with LB-100 plus atezolizumab. Enrollment in that specific trial is paused pending review by the Institutional Review Board.
Key figures
- Offering Price
- 6.31
- Shares Offered
- 2366503
- Shares Outstanding
- 15278806
- Last sale price
- 7.04
- Pre funded warrants
- 258859
- Pre funded warrant price
- 6.3099
- As adjusted ntbv per share
- 1.8
- Net tangible book value per share
- 0.79
- Dilution per share to new investors
- 4.51
Price after filing
Close on the filing date to close N calendar days later (from $7.00). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.